Revolution Biomanufacturing

Revolution Biomanufacturing is a private, U.S.-based biomanufacturing services company founded in 2020, headquartered in Cambridge, Massachusetts. It provides a comprehensive suite of development and manufacturing services for mRNA, cell, and gene therapies, positioning itself as a specialized CDMO for the personalized medicine sector. The company emphasizes its status as a 100% American-owned, Disabled Veteran-Owned, and Woman-Owned business, aiming to differentiate itself through agility, regulatory expertise, and a focus on patient-specific therapies. Its business model is service-based, generating revenue through client partnerships rather than developing its own therapeutic pipeline.

Integrated bioprocessing platform for mRNA, cell, and gene therapies, encompassing advanced mRNA design (UTR/codon optimization), DNA template engineering, in vitro transcription (IVT) process development, lipid nanoparticle (LNP) formulation, downstream purification, and flexible cGMP manufacturing.

Revolution Biomanufacturing competes in a crowded CDMO market against giants like Lonza and Catalent, as well as many specialized firms. It differentiates by focusing on personalized medicine batches, mRNA/LNP expertise, and its unique ownership profile, but must prove it can reliably execute at scale to win business from well-funded competitors.